The diagnostics technology developer picked up Jemincare and Haier Biomedical for its second funding round since spinning off from parent company 3D Medicines in 2018.

Softbank China and Sinopharm-CICC Capital returned for a series B-plus round after backing the online pharmacy's 2019 series B.

The immuno-oncology therapy developer filed to raise up to $50m, two years after securing money from investors including Biomed Realty and Alexandria Real Estate Equities.

The bioelectronic medicine developer has been snapped up by Astellas, two years after the latter took part in its series A round.

Q&A with Rob Coppedge, chief executive, EHV

The short bowel syndrome therapy developer has added $110m to the $35m with which it emerged from stealth in January.

Taiho Ventures and SR One co-led a series A round that will fund the early clinical progress of Dren's cancer and protein-depletion drug candidates.

Evotec and Boehringer Ingelheim Venture Fund returned in a $25.9m round for the autoimmune disease drug developer having first invested three years ago.

Topas Therapeutics, which is exploiting University of Hamburg research, has pocketed $26m in its series B round.

The round was led by $8m from Leaps by Bayer and increased the microbiome skin treatment developer's total funding to $34m.